A Prospective Randomized Controlled Clinical Study to Investigate the Efficacy and Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Switched from Continuous Erythropoietin Receptor Activator Treatment

被引:2
作者
Sezai, Akira [1 ]
Abe, Masanori [2 ]
Maruyama, Takashi [2 ]
Taoka, Makoto [1 ]
Sekino, Hisakuni [3 ]
Tanaka, Masashi [1 ]
机构
[1] Nihon Univ, Sch Med, Dept Cardiovasc Surg, Tokyo 1738610, Japan
[2] Nihon Univ, Sch Med, Div Nephrol Hypertens & Endocrinol, Dept Internal Med, Tokyo 1738610, Japan
[3] Sekino Hosp, Tokyo 1710014, Japan
关键词
renal anemia; heart failure; hypoxia-inducible factor-prolyl hydroxylase inhibitor; erythropoiesis-stimulating agent; erythropoietin; ROXADUSTAT; ALPHA;
D O I
10.3390/jcm13102764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: Chronic kidney disease (CKD) and anemia are independent prognostic factors for heart failure. In recent years, hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors have become available for the treatment of renal anemia. This prospective randomized controlled study aimed to investigate the effects of switching from a continuous erythropoietin receptor activator (CERA) to one of four HIF-PH inhibitors in patients with chronic heart failure and renal anemia. Methods: Forty patients were randomized by the envelop method to receive treatment with roxadustat, daprodustat, vadadustat, or molidustat. The primary endpoint was the change in the hemoglobin (Hb) level. Secondary endpoints included changes in erythropoietin, changes in free T3, free T4, and thyroid-stimulating hormone (TSH), adverse effects, and drug dose increases and decreases. This study was preregistered in the University Hospital Medical Information Network Clinical Trials Registry (study ID: UMIN000041651). Results: We found no statistically significant difference between Hb levels with HIF-PH inhibitors and CERA, but at month 6, the Hb level was significantly higher with roxadustat than with vadadustat and daprodustat. Erythropoietin decreased significantly after switching to HIF-PH inhibitors. HIF-PH inhibitors had various significant effects on free T3, free T4, and TSH. No adverse events occurred. The doses of some drugs had to be increased or decreased. Conclusions: In patients with heart failure and renal anemia receiving CERA, Hb, NT-ProBNP, and renal function were similar after switching from CERA to HIF-PH inhibitors. The individual HIF-PH inhibitors appear to have different effects on anemia and thyroid function. However, because this was a single-center study with a limited sample size, the efficacy and potential limitations of HIF-PH inhibitors need to be further clarified.
引用
收藏
页数:10
相关论文
共 15 条
  • [1] Anemia in Heart Failure Still Relevant?
    Beverborg, Niels Grote
    van Veldhuisen, Dirk J.
    van der Meer, Peter
    [J]. JACC-HEART FAILURE, 2018, 6 (03) : 201 - 208
  • [2] Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
    Fishbane, Steven
    Pollock, Carol A.
    El-Shahawy, Mohamed
    Escudero, Elizabeth T.
    Rastogi, Anjay
    Van, Bui Pham
    Frison, Lars
    Houser, Mark
    Pola, Maksym
    Little, Dustin J.
    Guzman, Nicolas
    Pergola, Pablo E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (04): : 850 - 866
  • [3] Effect of Roxadustat on Thyroid Function in Patients With Renal Anemia
    Haraguchi, Takuya
    Hamamoto, Yoshiyuki
    Kuwata, Hitoshi
    Yamazaki, Yuji
    Nakatani, Susumu
    Hyo, Takanori
    Yamada, Yuichiro
    Yabe, Daisuke
    Seino, Yutaka
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 109 (01) : e69 - e75
  • [4] Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Heart Failure with Preserved Ejection Fraction
    Imamura, Teruhiko
    Hori, Masakazu
    Tanaka, Shuhei
    Kinugawa, Koichiro
    [J]. MEDICINA-LITHUANIA, 2021, 57 (12):
  • [5] Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
    Imamura, Teruhiko
    Ueno, Yohei
    Kinugawa, Koichiro
    [J]. JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2021, 8 (12)
  • [6] Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
    Iso, Takashi
    Matsue, Yuya
    Mizukami, Akira
    Tokano, Takashi
    Isoda, Kikuo
    Suwa, Satoru
    Miyauchi, Katsumi
    Yanagisawa, Naotake
    Okumura, Yasuo
    Minamino, Tohru
    [J]. ESC HEART FAILURE, 2022, 9 (06): : 4291 - 4297
  • [7] Erythropoietin therapy improves endothelial function in patients with non-dialysis chronic kidney disease and anemia (EARNEST-CKD) A clinical study
    Lim, Jina
    Yu, Chung Jo
    Yu, Hoon
    Ha, Sang Jin
    [J]. MEDICINE, 2021, 100 (42) : E27601
  • [8] Anemia of cardiorenal syndrome
    McCullough, Peter A.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2021, 11 (01) : 35 - 45
  • [9] Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia
    Nakamura, Makiko
    Imamura, Teruhiko
    Sobajima, Mitsuo
    Kinugawa, Koichiro
    [J]. HEART AND VESSELS, 2023, 38 (02) : 284 - 290
  • [10] Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome
    Palazzuoli, Alberto
    Quatrini, Ilaria
    Calabro, Anna
    Antonelli, Giovanni
    Caputo, Maria
    Campagna, Maria S.
    Franci, Beatrice
    Nuti, Ranuccio
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2011, 11 (01) : 43 - 48